Sensipar patient brochure misleading, US FDA tells Amgen
This article was originally published in Scrip
Executive Summary
A patient brochure forAmgen's hyperparathyroidism drug Sensipar (cinacalcet) is false and misleading because it omits and minimises risks and broadens the medicine's indication, the US FDAsaid. The brochure omits the serious risk of adynamic bone disease and the need for monitoring of hepatically impaired patients. The presentation of side- effects information minimises the severity, frequency and duration of nausea and vomiting. The promotion also misleadingly suggests Sensipar is indicated for all patients on dialysis, rather than just those who require treatment for secondary hyperparathyroidism with chronic kidney disease. Amgen said it was working with the FDA to address its concerns and has stopped distributing the brochure.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.